Tolerability Profile of Atypical Antipsychotics in Children and Adolescents
- 1 January 2001
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pediatric Drugs
- Vol. 3 (12), 927-942
- https://doi.org/10.2165/00128072-200103120-00005
Abstract
Antipsychotics are frequently used in the treatment of a variety of neuropsychiatric conditions in children and adolescents. Atypical antipsychotics have come to the forefront in child psychiatry due largely to their tolerability profiles as well as their efficacy. Potential treatment options include clozapine, risperidone, olanzapine, quetiapine and ziprasidone. A number of studies investigating the use of clozapine have been published in children; however, owing to the frequent monitoring required for agranulocytosis, the use of clozapine may be restricted to patients with treatment-refractory disease. With accumulating data on the development of glucose intolerance in adults receiving clozapine, closer monitoring of bodyweight and fasting blood glucose is imperative. Clozapine also has an increased seizure risk, therefore a baseline electroencephalogram should be performed, as well as continued vigilance for this adverse effect. Risperidone is an atypical antipsychotic that is generally well tolerated and numerous studies have been published investigating this drug in children. Unlike clozapine, its receptor interaction profile lends itself toward increased risk of extrapyramidal symptoms (EPS) and hyperprolactinaemia. Bodyweight gain is a common adverse effect, although somewhat less than that reported with olanzapine. Baseline liver function studies prior to initiation of this medication are recommended. Risperidone-induced mania has been reported in adults and, therefore, increased caution should be used when deciding to treat children and adolescents with risperidone, particularly in those with a predisposition toward mania. Olanzapine, like risperidone, has also been associated with onset of mania in adults. Olanzapine has a receptor profile that results in significant risk for bodyweight gain and sedation. Furthermore, this drug has been linked to the development of glucose intolerance; thus, it is important to monitor bodyweight and fasting blood glucose on a frequent basis. Less information is known about quetiapine in children and adolescents. Reports about its efficacy and tolerability vary. Quetiapine appears to have increased risk for sedation and bodyweight gain, albeit less than that of olanzapine. The compound appears to be less likely to induce EPS. Finally, ziprasidone has recently been approved for use in the adult population. This compound, in terms of its receptor profile, has more in common with risperidone. This suggests a potential for increased risk of EPS and hyperprolactinaemia. It also has an increased risk of QTc prolongation; thus, a baseline electrocardiogram is suggested, particularly in those patients with a history of cardiovascular illness. Lack of evidence for bodyweight gain with ziprasidone is a considerable advantage.Keywords
This publication has 90 references indexed in Scilit:
- Paediatric uses of atypical antipsychoticsExpert Opinion on Pharmacotherapy, 2000
- An open-label study of olanzapine in children with PDDSchizophrenia Research, 2000
- Olanzapine in the treatment of bipolar-disorder in juvenilesSchizophrenia Research, 2000
- Elevated Prolactin in Pediatric Patients on Typical and Atypical AntipsychoticsJournal of Child and Adolescent Psychopharmacology, 1999
- An open trial of clozapine in neuroleptic-resistant childhood-onset schizophreniaThe British Journal of Psychiatry, 1997
- Use of Risperidone in Pervasive Developmental Disorders: A Case SeriesJournal of Child and Adolescent Psychopharmacology, 1996
- Risperidone in the Treatment of Children and Adolescents with Schizophrenia: A Retrospective StudyJournal of Child and Adolescent Psychopharmacology, 1996
- ICI 204,636 (SEROQUEL™): A Dibenzothiazepine Atypical Antipsychotic. Review of Preclinical Pharmacology and Highlights of Phase II Clinical TrialsCNS Drug Reviews, 1995
- Risperidone Treatment of Children and Adolescents: Increased Risk of Extrapyramidal Side Effects?Journal of Child and Adolescent Psychopharmacology, 1995
- Risperidone Effects in Treatment-Resistant Adolescents: Preliminary Case ReportsJournal of Child and Adolescent Psychopharmacology, 1995